How have AVXL and NERV total returns compared?

Over the past 10 years, AVXL delivered -7.93% and NERV delivered -29.77% annualized total return. Past performance doesn't predict future results.

Anavex Life Sciences Corp. (AVXL) vs Minerva Neurosciences, Inc. (NERV)

A side-by-side comparison of Anavex Life Sciences Corp. and Minerva Neurosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AVXL

Anavex Life Sciences Corp.

$149M

$1.61HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT

NERV

Minerva Neurosciences, Inc.

$160M

$3.43HealthcareDelayed quote: Oct 6, 2026, 12:24 PM EDT

Total return — AVXL vs NERV

growth of $100 · dividends reinvested · last 10y

AVXL -56.2% (-7.9%/yr)NERV -97.1% (-29.7%/yr)AVXL compounded faster over this window

Log scale — wide-divergence pair

AVXL NERV

AVXL vs NERV: by the numbers

•NERV is the larger company ($160M vs $149M market cap).

Metrics side by side

Valuation

Metric	AVXL	NERV
P/B ratio	1.33	N/A

Profitability

Metric	AVXL	NERV
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	0.00%	0.00%
ROE	-21.38%	N/A
ROIC	-27.25%	-38.56%

Growth (annualized)

Metric	AVXL	NERV
Total return CAGR (5Y)	-37.74%	-22.14%

Frequently asked

How have AVXL and NERV total returns compared?: Over the past 10 years, AVXL delivered -7.93% and NERV delivered -29.77% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AVXL analysis Full NERV analysis Interactive comparison tool

Dig into the metrics

Anavex Life Sciences ROE Minerva Neurosciences ROE Anavex Life Sciences operating margin Minerva Neurosciences operating margin Anavex Life Sciences revenue growth Minerva Neurosciences revenue growth Anavex Life Sciences free cash flow Minerva Neurosciences free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.